An observational study in Septic Shock and Fluid Resuscitation, sponsored by Australian and New Zealand Intensive Care Research Centre. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Australian and New Zealand Intensive Care Research Centre · Observational
A prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.
This study is a prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.
The investigators will include four multicentre, open-label, randomised, clinical trials:
All four trials have all received relevant approval from a research ethics committee with a locally appropriate method of obtaining consent. These trials are prospectively chosen prior to the results of any individual trial being known because they are investigating the same broad question in patients with acute septic shock across several countries. The investigators of these trials collaborated to harmonise data and outcomes as far as possible across all trials to facilitate an IPDMA.
The aims to provide high level evidence to address the question of whether a fluid sparing/early vasopressor approach or a liberal fluid/later vasopressor approach to initial haemodynamic resuscitation in septic shock results in improved outcomes, including mortality.
862 studies on the registry are indexed under Shock, Septic; 206 are open to participants now.
This study's planned enrollment of 7,838 is above the median of 100 across 298 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 48 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All trials include adult patients requiring resuscitation for hypotension or hypoperfusion due to suspected sepsis as defined in the original studies. Participants may be enrolled in the emergency department, acute care ward or intensive care unit.
Participants of the ARISE FLUIDS, CLASSIC, CLOVERS \& EVIS trials who had:
Exclusion criteria:
Participants not in the ARISE FLUIDS, CLASSIC, CLOVERS \& EVIS trials
A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
Other: Vasopressors
A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
Other: Fluids
A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
All-cause mortality at 90 days post randomisation
Death from any cause at 90 days after randomisation
Time frame: 90 days
Time from randomisation to death
Time from randomisation to death
Time frame: Up to day 90
Incidence of mechanical ventilation
Commencement of mechanical ventilation from randomisation until day 90 post-randomisation
Time frame: from randomisation until day 90 post-randomisation
Incidence of acute renal replacement therapy
Commencement of renal replacement therapy from randomisation until day 90 post-randomisation
Time frame: from randomisation until day 90 post-randomisation
Days alive free of organ support at 28 days post randomisation
days the patient is alive and receiving nil organ support from from randomisation until day 28 post-randomisation
Time frame: from randomisation until day 28 post-randomisation
Duration of hospital stay
Length of time in hospital from randomisation until death or hospital discharge or day 90 post-randomisation
Time frame: From randomisation until day 90 post-randomisation
Incidence of serious adverse events
Number of adverse events from randomisation until day 90 post-randomisation
Time frame: from randomisation until day 90 post-randomisation
Duration of intensive care unit (ICU) stay
Length of time in ICU from randomisation until death or hospital discharge or day 90 post-randomisation
Time frame: From randomisation until day 90 post-randomisation
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian and New Zealand Intensive Care Research Centre